Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma
J Natl Compr Canc Netw (2019) 17:615-617.
Abstract
According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations.
MeSH terms
Note
Publication Date: 2019-05-01.
Back
Last updated on Friday, December 06, 2019